PARP inhibitors in ovarian cancer maintenance are facing access pressure

Reading the signal

PARP inhibitors (olaparib, niraparib, rucaparib) entered ovarian cancer maintenance based on pivotal trials demonstrating progression-free survival benefit, with subgroup analyses showing the benefit concentrated in BRCA-mutated and homologous recombination deficient (HRD) populations. The class was endorsed by guidelines and gained formulary placement quickly across major markets in 2018 to 2020.

The 2024 to 2026 access environment has shifted:

• Prior-authorisation criteria have tightened, often requiring documented BRCA or HRD status with specific testing thresholds
• Some payers have introduced post-marketing evidence demands for the broader (non-BRCA, non-HRD) eligible population in indications where label coverage is broader than the strongest evidence base
• The overall-survival readouts from the pivotal trials have not always supported the progression-free survival benefit at the same level, with implications for cost-effectiveness reassessment
• The eligible-population framing is being revisited in light of subsequent evidence on which patients benefit most

The commercial trajectory has flattened relative to early projections, with some markets showing real-world utilisation below the eligible-population estimate.

Commercial implications

For sponsors of PARP assets and adjacent ovarian cancer pipeline:

1. Real-world cohort generation is now the price-and-coverage-defending asset, not a post-launch optimisation. Sponsors with active real-world cohorts in BRCA, HRD-positive non-BRCA, and HRD-negative populations are positioned to defend the indication-by-indication coverage conversation.
2. The OS-versus-PFS conversation is now structural, not residual. Indications where the OS benefit is more contested face access pressure that the PFS benefit alone does not resolve.
3. Adjacent ovarian cancer assets (maintenance combinations, novel mechanisms) face the same operational environment. The PARP experience is informative for what to anticipate.

What we are watching

• Updated guideline frames as long-term outcomes data continues to accumulate
• Payer-side coverage evolution and the rate at which indication-specific tightening continues
• Late-stage ovarian cancer pipeline (combinations, novel mechanisms) and how it positions relative to the contested PARP conversation